Opdualag (nivolumab + relatlimab-rmbw) Patient Assistance Program
Don’t let the high cost of brand dual checkpoint inhibitor disrupt your melanoma treatment. We help eligible patients access Opdualag (nivolumab and relatlimab-rmbw IV infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Opdualag (nivolumab + relatlimab-rmbw) is FDA-approved for treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma. First fixed-dose combination of anti-PD-1 (nivolumab/Opdivo) and anti-LAG-3 (relatlimab — the first FDA-approved LAG-3 inhibitor) — dual immune checkpoint blockade with distinct mechanisms.
- Without assistance, Opdualag costs commonly run approximately $28,000+ per infusion.
- Through AffordMyPrescriptions, qualifying patients can access Opdualag for a flat $69.95 per month.
- Other melanoma immunotherapy: nivolumab (Opdivo) monotherapy, pembrolizumab (Keytruda) monotherapy, nivolumab + ipilimumab (Opdivo + Yervoy — historically most-effective combo, higher toxicity), Tecentriq for combinations, cemiplimab (Libtayo). Melanoma-specific targeted therapy: BRAF inhibitors (dabrafenib, encorafenib, vemurafenib) + MEK inhibitors (trametinib, binimetinib, cobimetinib) for BRAF V600E/K mutations. Amtagvi (lifileucel — TIL therapy, 2024). Comprehensive tumor testing (BRAF, PD-L1, TMB, MSI). Melanoma Research Foundation resources.
What is Opdualag Prescription Assistance Program?
The Opdualag Patient Assistance Program helps eligible patients access this dual checkpoint inhibitor at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Opdualag PAP enrollment for a flat $69.95 per month — so you never face a gap in your Opdualag melanoma therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Opdualag enrollment — so you never face a gap in your advanced melanoma treatment.
Pharmacy Price Comparison
- Without assistance, Opdualag costs tens of thousands per infusion. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Nivolumab + ipilimumab alt | ~$40,000/infusion | Alt dual checkpoint combo |
| Cancer center pharmacy | ~$29,000/infusion | Save substantially |
| Community oncology | ~$28,000/infusion | Save substantially |
| Hospital outpatient | ~$28,500/infusion | Save substantially |
| 340B-eligible institution | ~$23,000/infusion | Save substantially |
| Nivolumab monotherapy alt | ~$15,000/infusion | Alt PD-1 monotherapy |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Opdualag — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Opdualag Prescription Program?
The Opdualag Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Opdualag offers improved efficacy vs anti-PD-1 monotherapy with reduced toxicity vs anti-PD-1/anti-CTLA-4 combination. Comprehensive melanoma tumor testing (BRAF, PD-L1, TMB) informs treatment selection.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Opdualag assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Opdualag is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Opdualag:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $28,000–$29,000/infusion even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Opdualag assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Opdualag Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Opdualag:
Opdualag is the first fixed-dose combination anti-PD-1 (nivolumab) + anti-LAG-3 (relatlimab) — dual immune checkpoint blockade with complementary mechanisms. LAG-3 (Lymphocyte Activation Gene-3) is an immune checkpoint distinct from PD-1 and CTLA-4. Improved efficacy vs anti-PD-1 monotherapy with lower toxicity than anti-PD-1/anti-CTLA-4 combos.
How It Works:
Advanced melanoma requires effective systemic therapy. Immune checkpoint inhibitors revolutionized melanoma outcomes — anti-PD-1 monotherapy (nivolumab, pembrolizumab) improved survival; anti-PD-1 + anti-CTLA-4 combinations (Opdivo + Yervoy) further improved response rates but with higher immune-related toxicity. The balance between efficacy and tolerability is central to treatment selection. LAG-3 (Lymphocyte Activation Gene-3) is an immune checkpoint expressed on activated T-cells and Tregs — inhibiting T-cell activation, particularly in exhausted T-cells. Relatlimab is an anti-LAG-3 monoclonal antibody. Combined with nivolumab (anti-PD-1) in the Opdualag fixed-dose combination — dual checkpoint blockade with complementary mechanisms and reduced toxicity vs anti-PD-1/anti-CTLA-4 combos. The RELATIVITY-047 trial demonstrated improved progression-free survival vs nivolumab monotherapy in previously untreated advanced melanoma.
Form and Use:
Opdualag IV infusion every 4 weeks. Fixed-dose nivolumab + relatlimab. Given at a cancer center or infusion suite. Immunotherapy toxicity monitoring is essential. Continue until disease progression or unacceptable toxicity.
Generic Availability:
No generic Opdualag. Other melanoma immunotherapy (all brand): nivolumab (Opdivo) monotherapy, pembrolizumab (Keytruda) monotherapy, nivolumab + ipilimumab (Opdivo + Yervoy — historically most-effective advanced melanoma combo, higher toxicity), atezolizumab (Tecentriq for combinations), cemiplimab (Libtayo). Melanoma-specific: BRAF inhibitors (dabrafenib, encorafenib, vemurafenib) + MEK inhibitors (trametinib, binimetinib, cobimetinib) — brand oral for BRAF V600E/K mutation-positive melanoma. Amtagvi (lifileucel — TIL therapy, 2024 FDA approval). Comprehensive tumor testing (BRAF, PD-L1, TMB, MSI). Melanoma Research Foundation, Melanoma International Foundation resources.
Warnings:
Immune-related adverse events (checkpoint inhibitor toxicities — colitis, hepatitis, pneumonitis, endocrinopathies including hypophysitis, thyroid dysfunction, adrenal insufficiency, type 1 diabetes; nephritis; dermatitis including SJS/TEN; myocarditis rare but potentially fatal; neurologic events; myositis; and others), infusion reactions, embryo-fetal toxicity. Other: fatigue, decreased appetite, diarrhea, rash. Immunotherapy toxicity is generally lower than with anti-PD-1/anti-CTLA-4 combos but higher than anti-PD-1 monotherapy. Multidisciplinary irAE management is essential.
FAQ (Frequently Asked Questions)
How much does Opdualag cost without insurance?
$28,000–$29,000 per infusion at cancer centers. With every-4-week dosing, monthly cost is $28,000+. Patient Assistance Programs are essential.
How is Opdualag different from Opdivo (nivolumab) alone?
Opdualag is a fixed-dose combination of anti-PD-1 (nivolumab) + anti-LAG-3 (relatlimab). Dual checkpoint blockade improves progression-free survival vs nivolumab monotherapy in previously untreated advanced melanoma (RELATIVITY-047 trial). LAG-3 is a distinct immune checkpoint — complementary to PD-1 blockade.
How is Opdualag different from Opdivo + Yervoy?
Both are dual immune checkpoint combinations. Opdivo + Yervoy (anti-PD-1 + anti-CTLA-4) is historically the most-effective advanced melanoma combo but with higher immune-related toxicity. Opdualag (anti-PD-1 + anti-LAG-3) improves efficacy vs anti-PD-1 monotherapy with lower toxicity than anti-PD-1/anti-CTLA-4 combos — a different efficacy/toxicity balance. Choice depends on individual patient factors and tolerability.
What is LAG-3 and why is it important?
LAG-3 (Lymphocyte Activation Gene-3) is an immune checkpoint expressed on activated T-cells and Tregs — inhibiting T-cell activation, particularly in exhausted T-cells. Relatlimab (in Opdualag) is the first FDA-approved LAG-3 inhibitor — adding a distinct mechanism to the immune checkpoint inhibitor landscape.
What are Opdualag side effects?
Immune-related adverse events (irAEs) — any organ affected including colon, liver, lung, endocrine glands, kidney, skin, heart, muscle, nerves. Fatigue, decreased appetite, diarrhea, rash. Prompt irAE recognition and management with corticosteroids or other immunosuppressants is critical. A multidisciplinary team is helpful.
Take Control of Your Medication Costs
Dual checkpoint blockade transformed advanced melanoma survival. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.